Beta Drugs Ltd Q2 FY26 Results & Concall Highlights: Capex ₹9.45 Cr

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Published 19 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.8K Cr

Beta Drugs plans to grow at a robust pace of 20-25% annually, as emphasized multiple times in the call. Beta Drugs aims to grow at a consistent pace of 20-25% annually, backed by a robust pipeline and strong execution (Page 15, Rahul Batra closing comments).

From Beta Drugs Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

📊 Revenue & Sales Performance

→Beta Drugs plans to grow at a robust pace of 20-25% annually, as emphasized multiple times in the call.
→Export sales are expected to see significant growth in the second half of FY26, potentially crossing Rs.100 crores, up from Rs.43 crores in the first half.
→The CDMO business grew 8% YoY and is expected to maintain steady contributions by adding new products and partners.
→In the domestic market, new molecule launches and own branded products are expected to drive growth, including two NDDS products planned for next year.
→The dermatology/cosmetic division aims for Rs.30-50 crores in sales over the next 3-5 years, focusing on scaling current SKUs before launching new ones.
→In-licensing and biosimilars are strategic growth areas, with potential product launches in 3-4 years.
→Overall, the company targets sustained top-line growth backed by product pipeline expansions and entry into new regulated markets.

📈 Profitability & Margins

→Beta Drugs aims to grow at a consistent pace of 20-25% annually, backed by a robust pipeline and strong execution (Page 15, Rahul Batra closing comments).
→EBITDA margins are expected to remain stable between 23% and 25% for FY26 (Page 8).
→Exports, currently tender-driven with slower first-half performance, are expected to grow significantly in the second half, potentially crossing Rs.100 crores (Page 12).
→Development of new products, including three drug filings and two new NDDS next year, will drive growth over the next 3-5 years (Page 5).
→Growth will also be supported by expansion in derma/cosmetic business projected to reach Rs.30-50 crores per year in 3-5 years (Page 10).
→Biosimilar entry planned within 3-4 years, potentially adding new revenue streams (Page 11).
→Working capital and receivables expected to normalize with volume growth; no major impact anticipated on profitability (Pages 13-14).

See what Beta Drugs Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→Beta Drugs acquired an oncology intermediate plant with a CAPEX of around Rs.9.45 crores; additional Rs.15-20 crores planned for building and machinery to operationalize it within 6-8 months.
→Purchased land for an intermediate plant and a corporate R&D center; final payments pending due to registry processes.
→Fixed asset additions amounting to approximately Rs.25 crores in H1FY26, including expenditure on buildings.
→Cash reserves are being held for new product development, potential inorganic growth opportunities, and in-licensing biosimilars.
→The company is planning biosimilar development with ongoing discussions and NDAs, aiming for product launches in 3-4 years.
→Investment in capacity expansion at Adley formulation plant to support domestic sales and CDMO growth.

💰 Fundraising & Capital Structure

→Currently, Beta Drugs Limited has no explicit mention of new fundraising plans through debt or equity in the call.
→The company has maintained some cash reserves mainly for new product development, inorganic growth opportunities, and potential biosimilar in-licensing.
→Existing borrowings, including convertible debentures, are expected to be converted by June next year, which will reduce leverage.
→No specific new issuance of debt or equity was discussed during the call.
→The management emphasized using cash reserves for CAPEX, including the oncology intermediate plant and R&D facilities, but no fundraising linked to these was mentioned.

See what Beta Drugs Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

→The company had an order book that could not be processed fully by September, resulting in Rs.10-12 crores of orders to be dispatched in October and November (Page 11).
→Exports are tender-driven, with most tenders awarded between October and December, leading to expected higher sales from January onwards (Pages 7 and 12).
→In October alone, three major tenders were filed, with two more planned in different geographies soon (Page 12).
→The company expects export revenues to cross Rs.100 crores in the second half of FY26, nearly doubling from Rs.43 crores in the first half (Page 12).
→The order backlog and tender pipeline indicate strong growth momentum to meet the annual target growth of 20-25% (Pages 11 and 12).

Key Metrics

How does Beta Drugs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Beta Drugs Ltd

See full Pharmaceuticals & Biotechnology sector rankings

Price

₹2,328

Market Cap

₹2.8K Cr

P/E Ratio

62.0

Beta Drugs Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹94 Cr, net profit ₹9 Cr.

Full financials →

What Beta Drugs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Alivus Life (Q2 FY26)
Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Key concall takeaways from Alivus Life's Q2 FY26 earnings call — and how it ranks against sector…
Solara Active Pharma Sciences Ltd (Q2 FY26)
Current facility capacity utilization is about 70%, with capacity available to serve new customers. Key concall takeaways from Solara Active's Q2 FY26 earnings…
Sun Pharma.Inds. (Q2 FY26)
India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Key concall…
Zydus Lifesci. (Q2 FY26)
Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Beta Drugs Ltd Q2 FY26 results?

What is Beta Drugs Ltd share price analysis?

Beta Drugs Ltd currently shows a neutral. The stock trades at a P/E of 62.0 with a market cap of ₹2,828 Cr. Investors should review the full earnings analysis for detailed insights.

Is Beta Drugs Ltd planning capital expenditure?

Beta Drugs acquired an oncology intermediate plant with a CAPEX of around Rs.9.45 crores; additional Rs.15-20 crores planned for building and machinery to operationalize it within 6-8 months.

Keep Beta Drugs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.